GlassScriptPhysician profile
Michelle Bravo
NPI 1881191245
$1,563.49
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $531 · 2024: $719 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $441.10 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Abbvie INC. | $424.06 | 2022-2025 | Botox |
| Pfizer INC. | $193.54 | 2023-2024 | |
| Avita Medical Americas, LLC | $158.33 | 2024 | |
| Access Pro Medical, LLC | $79.42 | 2023 | Matriderm |
| Lilly USA, LLC | $60.08 | 2022-2023 | Emgality |
| Integra Lifesciences Corporation | $57.18 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Teva Pharmaceuticals USA, INC. | $32.91 | 2023 | Ajovy |
| Lundbeck LLC | $32.43 | 2025 | Vyepti |
| Impel Pharmaceuticals INC. | $24.18 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $24.05 | 2022 | |
| Hydrofera LLC | $19.33 | 2023 | Hydrofera Blue |
| Ipsen Biopharmaceuticals, INC | $16.88 | 2023 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.